340B Discounts Withheld Through Contract Pharmacy Restrictions Equal 10% of Overall Program Sales
Executive Summary
Data from the US Health and Human Services Department quantify the financial impact of manufacturer 340B “integrity” initiatives on hospitals and other providers over the past several months.
You may also be interested in...
Manufacturer Restrictions On 340B Discounts Cut Contract Pharmacy-Based Savings 23% Or More
Hospital survey seeks to determine the financial impact of manufacturer limits on the 340B discounts they provide on drugs dispensed through pharmacies acting under contract with the program's covered entities.
Drug Pricing Day At The US Supreme Court
Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.
340B Court Ruling Offers Manufacturers Short-Term Reprieve In Contract Pharmacy Dispute
Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.